Acute Kidney Injury Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanisms of Action, Routes of Administration and Developments – Digital Journal

The acute kidney injury pipeline includes more than 30 key companies working continuously to develop more than 30 treatment therapies for acute kidney injury, analysis of clinical trials, therapies, mechanisms of action, routes of administration and developments, analyzes DelveInsight.

Overview of acute kidney injury

Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a sudden episode of kidney failure or kidney damage that occurs within a few hours or days. AKI causes waste products to build up in the blood, making it harder for the kidneys to maintain the proper fluid balance in the person’s body. AKI can also affect other organs, such as the brain, heart, and lungs. Acute kidney damage is common in patients in the hospital, in intensive care units, and especially in older adults.

“Acute Kidney Injury Pipeline Insights, 2022” DelveInsight’s report outlines comprehensive insights into the current clinical development scenario and growth prospects in the Acute Kidney Injury market.

The Acute Kidney Injury Pipeline report includes an in-depth commercial and clinical assessment of the pipeline’s products from the pre-clinical development stage to the commercial stage. The report also includes a detailed description of the drug, including the drug’s mechanism of action, clinical trials, NDA approvals (if any), and product development activities that include the technology, collaborations, mergers, acquisition, financing, designations, and other product-related details.

Some key takeaways from the Acute Kidney Injury Pipeline Report:

• Companies around the world are working diligently to develop novel treatment therapies for Acute Kidney Injury with notable success over the years. Acute Kidney Injury Market major players such as – Bessor Pharma, XORTX Therapeutics, RegeneRx Biopharmaceuticals, Sentien Biotechnologies, Pharming Group, Guard Therapeutics, Angion Biomedical, AM Pharma Holding, and others are developing therapies for the treatment of acute kidney injury

• Acute Kidney Injury New therapies such as – BP 1002, Oxipurinol, Timbetasin, SBI 101, Conestat alfa, RMC 035, ANG-3777, Human recombinant alkaline phosphatase, and others are expected to have a significant impact on the Acute Kidney Injury market in the years to come.
• In November 2020, AM-Pharma initiated a study entitled “A DB, Placebo-Controlled, Two-Armed Parallel Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for the Treatment of Patients With SA-AKI”
• In September 2021 AM-Pharma and Kyowa Kirin signed an exclusive license agreement to commercialize Ilofotase Alfa in Japan

Evaluation of the therapeutics pipeline for acute kidney injury

• Rating of Acute Kidney Injury by Product Type
• Acute kidney injury by stage and product type
• Assessment of acute kidney injury by route of administration
• Acute renal injury by stage and route of administration
• Acute Kidney Injury Assessment by Molecule Type
• Acute kidney injury by stage and molecular type

DelveInsight’s Acute Kidney Injury Report covers around 30+ products in different stages of clinical development, such as:

• Late Phase Products (Phase III)
• Mid-Stage Products (Phase II)
• Early-stage product (Phase I)
• Candidates for the pre-clinical phase and the discovery phase
• Retired and Inactive Candidates
• way of administration

New drugs for acute kidney injury in various stages of clinical development include:

• GP 1002: Better Pharma
• Oxipurinol: XORTX Therapeutics
• Timbetasine: RegeneRx Biopharmaceuticals
• SBI 101: Sentien Biotechnologies
• Conestat alfa: pharming group
• RMC 035: Guard Therapeutics
• ANG-3777: Angion Biomedical
• Human recombinant alkaline phosphatase: AM Pharma Holding

Get a free sample report in PDF format to learn more about the Acute Kidney Injury Pipeline Assessment – https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

Pipeline Analysis in Acute Kidney Injury:

The Acute Kidney Injury pipeline report provides insights into

• The report provides detailed insights into companies developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed for it by each company.
• It accesses the various therapeutic candidates classified into early stage, mid stage and late stage of development for the treatment of acute kidney injury.
• Key Acute Kidney Injury companies are involved in the targeted development of therapeutics with corresponding active and inactive (dormant or discontinued) projects.
• Drugs under development for acute kidney injury based on development stage, route of administration, target receptor, monotherapy or combination therapy, another mechanism of action, and molecular type.
• Detailed analysis of the collaborations (company-company collaborations and company-academic collaborations), licensing agreement and funding details for the future advancement of the Acute Kidney Injury market.

The report is based on data and information sourced from the investigator’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources. etc.

See the report for more Acute Kidney Injury product details. Download the Acute Kidney Injury pipeline report to learn more about the emerging therapies for Acute Kidney Injury

Acute Kidney Injury Pipelines Market Drivers

• Increasing prevalence of acute kidney injury
• Growing awareness of early injury prognosis

Acute Kidney Injury Pipeline Market Barriers

• Lack of effective therapeutic interventions to prevent or treat acute kidney injury
• High costs associated with treating acute kidney injury

Scope of insight into pipeline drugs for acute kidney injury

• Coverage: Worldwide
• Major Acute Kidney Injury Companies: Bessor Pharma, XORTX Therapeutics, RegeneRx Biopharmaceuticals, Sentien Biotechnologies, Pharming Group, Guard Therapeutics, Angion Biomedical, AM Pharma Holding and others
• Main therapies for acute kidney injury: BP 1002, Oxipurinol, Timbetasin, SBI 101, Conestat alfa, RMC 035, ANG-3777, Human recombinant alkaline phosphatase and others
• Therapeutic assessment in acute kidney injury: Current marketed and emerging therapies for acute kidney injury
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury Market Drivers and Acute Kidney Injury Market Barriers

Request a sample PDF report for the Acute Kidney Injury Pipeline Assessment and Clinical Trials

Table of Contents

Download the sample report in PDF format to learn more about medications and therapies for acute kidney injury

media contact
Name of the company: Delve Insight Business Research LLP
Interlocutor: Gaurav Bora
E-mail: Send e-mail
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
Federal State: NV
Country: United States
Website: https://www.delveinsight.com